234 related articles for article (PubMed ID: 19822515)
1. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
Shahrokni A; Rajebi MR; Saif MW
Clin Colorectal Cancer; 2009 Oct; 8(4):231-4. PubMed ID: 19822515
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Shahrokni A; Rajebi MR; Harold L; Saif MW
JOP; 2009 Mar; 10(2):215-20. PubMed ID: 19287123
[TBL] [Abstract][Full Text] [Related]
3. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics.
Saif MW
Anticancer Drugs; 2019 Apr; 30(4):431-434. PubMed ID: 30875351
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
6. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Rosmarin D; Palles C; Church D; Domingo E; Jones A; Johnstone E; Wang H; Love S; Julier P; Scudder C; Nicholson G; Gonzalez-Neira A; Martin M; Sargent D; Green E; McLeod H; Zanger UM; Schwab M; Braun M; Seymour M; Thompson L; Lacas B; Boige V; Ribelles N; Afzal S; Enghusen H; Jensen SA; Etienne-Grimaldi MC; Milano G; Wadelius M; Glimelius B; Garmo H; Gusella M; Lecomte T; Laurent-Puig P; Martinez-Balibrea E; Sharma R; Garcia-Foncillas J; Kleibl Z; Morel A; Pignon JP; Midgley R; Kerr D; Tomlinson I
J Clin Oncol; 2014 Apr; 32(10):1031-9. PubMed ID: 24590654
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.
Lubner SJ; Loconte NK; Holen KD; Schelman W; Thomas JP; Jumonville A; Eickhoff JC; Seo S; Mulkerin DL
Clin Colorectal Cancer; 2010 Jul; 9(3):157-61. PubMed ID: 20643620
[TBL] [Abstract][Full Text] [Related]
8. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Braun MS; Richman SD; Thompson L; Daly CL; Meade AM; Adlard JW; Allan JM; Parmar MK; Quirke P; Seymour MT
J Clin Oncol; 2009 Nov; 27(33):5519-28. PubMed ID: 19858398
[TBL] [Abstract][Full Text] [Related]
9. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
10. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
[TBL] [Abstract][Full Text] [Related]
11. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?
Saif MW; Sandoval A
Cutan Ocul Toxicol; 2008; 27(4):311-5. PubMed ID: 19037763
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Jordan K; Kellner O; Kegel T; Schmoll HJ; Grothey A
Clin Colorectal Cancer; 2004 May; 4(1):46-50. PubMed ID: 15207020
[TBL] [Abstract][Full Text] [Related]
13. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Hoff PM; Ansari R; Batist G; Cox J; Kocha W; Kuperminc M; Maroun J; Walde D; Weaver C; Harrison E; Burger HU; Osterwalder B; Wong AO; Wong R
J Clin Oncol; 2001 Apr; 19(8):2282-92. PubMed ID: 11304782
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
Saif MW
Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Small EJ
Cancer; 2005 Feb; 103(3):553-8. PubMed ID: 15612026
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Weekes CD; Nallapareddy S; Rudek MA; Norris-Kirby A; Laheru D; Jimeno A; Donehower RC; Murphy KM; Hidalgo M; Baker SD; Messersmith WA
Invest New Drugs; 2011 Oct; 29(5):1057-65. PubMed ID: 20306339
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
Do JE; Kim YC
Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
[TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Uchida K; Danenberg PV; Danenberg KD; Grem JL
BMC Cancer; 2008 Dec; 8():386. PubMed ID: 19105824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
